- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Impact of Cost on Patients' Access to Treatment
Zachary T. Bloomgarden, MD, MACE: We have to have rational drug pricing. We have to change, in such a fashion, to have the cost of drugs in America not differ from the cost of drugs in the United Kingdom, France, Germany, China, or Japan, for that matter. We need to have an effective approach to making drugs available for everyone.
Currently, individuals who have Medicare Part D have a huge burden of paying for drugs once they reach the so-called donut hole, and that certainly needs to change. But, most importantly, we have to stop confusing the cost of the drug, in terms of buying the product, [with] the cost of the drug in terms of its likelihood of ultimately affording benefit to the individual in question.
This is an area in which I fear that we’ve erred tremendously. We allow higher-cost versus lower-cost drugs to be prescribed less frequently, even though the higher-cost drugs may truly be better. So, we have to rethink some of our concepts.
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More
